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CROSS-SENSITIVITY BETWEEN STREPTOMYCIN
AND DIHYDROSTREPTOMYCIN*
FREDERICK J. WENZEL, B.S. AND STEPHAN EPSTEIN, M.D.
Conflicting reports about cross-sensitivity be-
tween streptomycin and dihydrostreptomycin
(DHS) prompted us to study this problem under
controlled conditions in sensitized guinea pigs.
MATERIALS AND METHODS
Albino guinea pigs weighing between 400 to 500
grams were used in groups of 10 animals. They were
prepared by four weekly subcutaneous injections
of 5 mgm of streptomycin or DHS, respectively,
mixed with Freund's adjuvant. One week after
the last preparatory injection, the animals were
tested intradermally with 0.1 cc of 1% solutions
of both streptomycin and DHS. The animals
later on were tested with a 1% solution of strepti-
dine; patch tests with 10% solutions of these
chemicals were also carried out.
Commercial streptomycin and dihydrostrepto-
mycin were usedf. Streptomycin can be considered
a pure preparation; however commercial DHS
contains about 3% streptomycin because it is pro-
duced from streptomycin by reduction. Accord-
ing to the U.S.P. a 3% contamination of DHS with
streptomycin is permissible. Our own studies
utilizing the maltol method (1, 2) confirmed an
admixture of 3% streptomycin. We purified the
commercial DHS by recrystallization so that the
contamination was only 1%.
RESULTS
All animals prepared with streptomycin became
allergic to this drug and gave strong delayed-
type reactions to intradermal tests; in most of
them patch tests were also positive. The intra-
dermal tests were characterized by indurated
papules 15 mm in diameter, exhibiting a marked
erythema. Numerous histologic examinations
confirmed the allergic nature of the reactions.
The histologic descriptions of these tests have
been presented elsewhere (3). Control tests on
non-sensitized animals produced no reactions at
all or only minor pink papules less than 7 mm in
diameter.
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Guinea pigs sensitized to streptomycin did not
react to DHS or streptidine. Of the more than
30 animals prepared with DIIS none became
allergic to this drug. However, in our first series
5 out of 8 animals prepared with commercial
DHS gave a delayed-type reaction to intradermal
tests with streptomycin. We suspected contamina-
tion of DHS with streptomycin as the cause of
this strange behavior and could demonstrate
that the contaminating amount of streptomycin
was sufficient to sensitize. Of 10 guinea pigs which
had been sensitized with the corresponding
amount of streptomycin (0.15 mgm as contrasted
to the 5 mgm in the original series) 3 animals
became allergic. When we attempted to sensitize
guinea pigs with a more purified DHS (contain-
ing only 1% streptomycin) only 1 animal out of 7
reacted. It is regrettable that we had no strepto-
mycin-free DHS available for this study. But the
drop in the number of sensitized animals corre-
sponds well with the decreased amounts of strep-
tomycin utilized for the sensitization. Therefore
these findings may be considered adequate evi-
dence that the "DHS guinea pigs" had been sensi-
tized by the contaminating streptomycin.
DISCUSSION AND COMMENTS
Our studies show that there is no cross-sensi-
tivity between streptomycin and DHS in guinea
pigs. This is also supported by our previous
studies (2) on cross-sensitivity between neomycin
and streptomycin; guinea pigs sensitized to neo-
mycin cross-reacted with streptomycin, but not
with DHS.
A survey of the literature, and of personal com-
munications from several physicians with wide
experience in the treatment of tuberculosis, indi-
cates that in general cross-sensitivity between
the two drugs is rare. This lack of cross-sensitivity
is surprising because, as Figure 1 shows, strepto-
mycin and DHS are very closely related chemi-
cally. The difference between the two drugs lies
in the streptose part of the molecule. In DHS the
aldehyde group of streptomycin is reduced to an
alcohol group. Apparently such a minor chemical
change is the reason for the great difference in the
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sensitization potential of these two drugs. Strep-
tomycin is notoriously a very potent sensitizer;
DHS is not. Among others, Hilt and Roederer (4)
emphasize the non-sensitizing character of DHS.
There are however some reports that claim cross-
sensitivity between streptomycin and DHS in
humans. Miller (5) as well as Sulzberger (6) re-
ported on patients who were allergic to strepto-
mycin and who also reacted to dihydrostrepto-
mycin. These authors assumed that there was
cross-sensitivity between the two drugs because
their patients had not been previously exposed to
DHS. Simon (7, 8) also claimed cross-sensitivity.
However, all these authors apparently were not
aware that commercial DHS is contaminated
with streptomycin. An analysis of their data
strongly suggests the possibility that the reac-
tions to tests with commercial DHS were not an
expression of cross-sensitivity, but rather were
due to the contaminating streptomycin or to in-
dependently developed sensitivity to DHS. The
degree of sensitivity to streptomycin in nurses
suffering from contact dermatitis apparently is
very high. Wilson (9) reports that 3 out of 6
streptomycin-sensitive nurses gave positive
patch tests to 0.01% dilutions. A 1% patch test
with commercial DHS would contain streptomy-
cm in sufficient concentration to cause a positive
patch test in a highly sensitive person. Absence of
cross-sensitivity between streptomycin and DHS
is also suggested by Hobson, et al. (10). These
authors treated 5 streptomycin sensitive pa-
tients with purified DHS without any sign of
sensitivity. They observed negative patch tests
to DHS in a number of streptomycin sensitive
patients. Livingood (11) also reported negative
intradermal tests to dihydrostreptomycin in 4
streptomycin sensitive patients. It appears
therefore that reports about cross-sensitivity
between streptomycin and DHS cannot be con-
sidered valid unless the patients gave also posi-
tive reactions to purified DHS. By the same
token, reports about sensitization following the
use of crude DHS (10) do not necessarily prove
sensitization to this chemical because, like our
guinea pigs, the patient may have become sensi-
tized to the contaminating streptomycin.
SUMMARY
1) Guinea pigs can be sensitized to strepto-
mycin, but not to dihydrostreptomycin (DHS).
2) Cross-sensitivity between these two anti-
biotics does not occur in guinea pigs.
3) Reactions to streptomycin in guinea pigs
prepared with DHS are due to contamination of
commercial DHS with streptomycin.
4) It seems doubtful that cross-sensitivity
between streptomycin and DHS exists in man.
Analysis of reports on cross-sensitivity between
streptomycin and DHS in man suggests that the
few reported instances of positive reactions to
DHS in nurses with streptomycin contact sen-
sitivity may have been due to the contaminating
streptomycin found in commercial DHS, or may
represent independently acquired sensitivity to
DHS.
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